Elanco Animal Health Incorporated (ELAN) | Investment Case

1. Company Snapshot

1.a. Company Description

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.

Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Show Full description

1.b. Last Insights on ELAN

Elanco Animal Health Incorporated's recent performance was positively driven by its robust product innovation and commercial execution. The company's 'Big 6' innovation portfolio is expected to contribute approximately $1.1 billion in 2026 revenue, supporting margin expansion and portfolio renewal. Additionally, products like Credelio Quattro and Zenrelia have shown rapid adoption and strong sequential growth. Analysts have given the stock a consensus rating of "Moderate Buy" (MarketBeat Ratings). The company's recent earnings release showed quarterly earnings of $0.13 per share, beating estimates (Zacks Consensus Estimate).

1.c. Company Highlights

Last Price	23.68
Change Percentage	2.38%
Open	23.51
Previous Close	23.13
Market Cap ( Millions)	11773
Volume	3631436
Year High	27.72
Year Low	8.33
M A 50	24.36
M A 200	21.11

FCF Yield	2.41%
Dividend Yield	0.00%
ROE	-3.51%
Debt / Equity	61.36%
Net Debt / EBIDTA	480.89%
Price To Book	1.8
Price Earnings Ratio	-50.72
Price To FCF	41.45
Price To sales	2.5
EV / EBITDA	21.11

2. Elanco's 2025 Earnings: A Year of Significant Delivery

Elanco's financial performance in 2025 was marked by significant delivery across all three priorities: growth, innovation, and cash. The company achieved 9% organic constant currency revenue growth in the fourth quarter, outperforming guidance for revenue, adjusted EBITDA, and adjusted EPS. Revenue from innovation exceeded expectations, reaching $892 million in 2025, with the fourth quarter being the largest quarter for innovation to date. Adjusted gross margin increased 30 basis points to 51.2%, driven by price, increased sales volumes, and mix benefits. Adjusted EPS was $0.13 in the quarter, a 7% decrease year-over-year due to an anticipated higher tax rate. The actual EPS came out at -$0.55544 relative to estimates at $0.11.

Publication Date: Feb -25

                                    📋 Highlights
                                    Q4 Organic Revenue Growth::
                                                9% organic constant currency revenue growth, outperforming guidance for revenue, adjusted EBITDA ($189M, +7%), and adjusted EPS ($0.13, -7% YoY).
Innovation Revenue::
                                                $892M in 2025, exceeding expectations; 2026 raised to $1.15B ($250M+ growth), driven by "big six" products like Credelio Quattro and Zenrelia.
Net Leverage Ratio::
                                                Improved to 3.6x (vs. 2026 target of 3.1–3.3x) and 3.0–3.5x by 2027, reflecting disciplined capital allocation and debt reduction.
Credelio Quattro Momentum::
                                                Fastest blockbuster in Elanco’s history, gaining U.S. broad-spectrum sales share and driving 2,600+ clinics to adopt complementary products.
Zenrelia Performance::
                                                Strong growth in $2B derm market, with double-digit gains in Europe (France, Italy, Spain) and best month (December) on record globally.

                                

Innovation Revenue and Future Outlook

The company's innovation revenue is expected to continue growing, with a commitment to at least another $250 million of growth in 2026, reaching $1.15 billion. This target is led by the "big six" major innovation products, including Credelio Quattro and Zenrelia, which are gaining traction in the global marketplace. As Jeff Simmons stated, "We are committing to at least another $250 million of growth in 2026 to $1.15 billion." The company's no-regrets approach to launches will continue in 2026, with data-driven decisions on ROI.

Segment Performance

The company's Pet Health business delivered 9% constant currency growth in the fourth quarter, driven by demand for key innovation products. The U.S. performance delivered 10% growth, while outside the U.S., the pet health business grew 8% in constant currency. The Farm Animal business also showed strong performance, with 17% growth in the U.S. The livestock business drove the Q4 beat, with protein markets expected to grow 5% in the U.S.

Valuation and Future Expectations

Analysts estimate next year's revenue growth at 5.2%. Elanco's current valuation metrics include a P/E Ratio of -56.5, P/B Ratio of 2.0, and EV/EBITDA of 18.97. The company's net debt to EBITDA ratio is 3.97, indicating a relatively high level of debt. For 2026, the company is guiding towards mid-single-digit top-line growth, high single-digit EBITDA growth, and low double-digit EPS growth. The guidance assumes the acquisition of AHV is not factored in.

Key Drivers and Challenges

The company's key drivers include the continued growth of its innovation products, particularly Credelio Quattro and Zenrelia. The derm market is expected to grow double-digits, driven by new competition. However, the company faces challenges, including inflationary pressures and higher cost of inventory, which may impact gross margin. The company's no-regrets approach to launches and funding R&D will also impact OpEx growth.

3. NewsRoom

Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

Apr -16

Source: prnewswire.com

Elanco Animal Health Incorporated $ELAN Shares Sold by Douglas Lane & Associates LLC

Apr -10

Source: defenseworld.net

Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*

Apr -09

Source: prnewswire.com

SG Americas Securities LLC Sells 32,403 Shares of Elanco Animal Health Incorporated $ELAN

Apr -05

Source: defenseworld.net

Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Moderate Buy” from Analysts

Apr -05

Source: defenseworld.net

Elanco Animal Health Incorporated (ELAN) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript

Mar -17

Source: seekingalpha.com

Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar -11

Source: seekingalpha.com

Elanco Animal Health Incorporated (ELAN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar -10

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.47%)

6. Segments

Pet Health

Expected Growth: 4.5%

Elanco's Pet Health segment growth of 4.5% is driven by increasing pet humanization, rising pet ownership, and growing demand for premium pet food and healthcare products. Additionally, the company's strategic acquisitions, expanded product portfolio, and strong veterinary relationships contribute to its growth momentum.

Farm Animal - Cattle

Expected Growth: 4.8%

Elanco Animal Health's cattle segment growth of 4.8% is driven by increasing demand for protein-rich food, rising adoption of precision livestock farming, and growing awareness of animal health and wellness. Additionally, Elanco's innovative products and services, such as its parasiticide and vaccine offerings, are contributing to the growth.

Farm Animal - Poultry

Expected Growth: 4.2%

Elanco's poultry segment growth of 4.2% is driven by increasing demand for protein-rich food, rising adoption of antibiotic-free products, and growing awareness of animal welfare. Additionally, Elanco's innovative vaccine portfolio and parasiticide products are addressing disease challenges in poultry, further fueling growth.

Farm Animal - Swine

Expected Growth: 4.0%

Elanco's Swine segment growth is driven by increasing global demand for protein, African Swine Fever (ASF) outbreaks, and rising adoption of antibiotic-free production. The 4.0% growth rate is also fueled by Elanco's innovative vaccine and parasiticide solutions, as well as its strategic partnerships with swine producers and veterinarians.

Farm Animal - Aqua

Expected Growth: 4.3%

Elanco's Aqua segment, focused on farm animal health, exhibits 4.3% growth driven by increasing global demand for protein-rich food, rising aquaculture production, and growing adoption of sustainable farming practices. Additionally, Elanco's innovative products and services, such as parasiticide treatments and nutritional solutions, address key health challenges in aquaculture, further fueling growth.

Contact Manufacturing

Expected Growth: 5.2%

Elanco Animal Health's Contact Manufacturing segment growth of 5.2% is driven by increasing demand for animal health products, expansion into emerging markets, and strategic partnerships. Additionally, investments in R&D and manufacturing capabilities have improved operational efficiency, enabling the company to capitalize on growing market trends.

7. Detailed Products

Rumensin

A feed additive used to improve feed efficiency and weight gain in cattle

Baytril

An antibiotic used to treat respiratory diseases in cattle and pigs

Clarisyn

A parasiticide used to control internal and external parasites in cattle

Improvac

A vaccine used to improve reproductive performance in pigs

Trifexis

A parasiticide used to prevent flea infestations and treat flea allergy dermatitis in dogs

Galliprant

A non-steroidal anti-inflammatory drug used to treat osteoarthritis in dogs

Intercept

A parasiticide used to prevent flea and tick infestations in dogs

8. Elanco Animal Health Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Elanco Animal Health Incorporated is moderate due to the presence of alternative products and services in the animal health industry.

Bargaining Power Of Customers

The bargaining power of customers for Elanco Animal Health Incorporated is low due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Elanco Animal Health Incorporated is moderate due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for Elanco Animal Health Incorporated is high due to the growing demand for animal health products and services.

Intensity Of Rivalry

The intensity of rivalry for Elanco Animal Health Incorporated is high due to the presence of established competitors in the animal health industry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	48.13%
Debt Cost	4.66%
Equity Weight	51.87%
Equity Cost	10.65%
WACC	7.77%
Leverage	92.78%

11. Quality Control: Elanco Animal Health Incorporated passed 2 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Intra-Cellular Therapies

A-Score: 5.3/10

Value: 6.0

Growth: 7.1

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.7

1-Year Total Return ->

Lantheus Holdings

A-Score: 4.9/10

Value: 4.0

Growth: 9.0

Quality: 8.0

Yield: 0.0

Momentum: 5.5

Volatility: 2.7

1-Year Total Return ->

Elanco Animal Health

A-Score: 4.4/10

Value: 2.7

Growth: 6.0

Quality: 3.9

Yield: 0.0

Momentum: 9.5

Volatility: 4.3

1-Year Total Return ->

Amneal Pharmaceuticals

A-Score: 4.2/10

Value: 4.0

Growth: 3.7

Quality: 3.4

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

Deciphera Pharmaceuticals

A-Score: 4.0/10

Value: 6.2

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

Catalent

A-Score: 2.7/10

Value: 3.1

Growth: 2.2

Quality: 2.2

Yield: 0.0

Momentum: 7.0

Volatility: 1.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

14.68%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.77%

Elanco Animal Health Incorporated - US28414H1032

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ELAN

1.c. Company Highlights

Strong Momentum

Average Quality

Medium Volatility

Earnings Beats

Revenues Beats

Average Growth

Lower Quality

Stable Momentum

Average Yield

Fairly Valued

Earnings Miss

Revenues Miss

Weak Momentum

Expensive

2. Elanco's 2025 Earnings: A Year of Significant Delivery

Innovation Revenue and Future Outlook

Segment Performance

Valuation and Future Expectations

Key Drivers and Challenges

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.47%)

6. Segments

Pet Health

Expected Growth: 4.5%

Farm Animal - Cattle

Expected Growth: 4.8%

Farm Animal - Poultry

Expected Growth: 4.2%

Farm Animal - Swine

Expected Growth: 4.0%

Farm Animal - Aqua

Expected Growth: 4.3%

Contact Manufacturing

Expected Growth: 5.2%

7. Detailed Products

Rumensin

Baytril

Clarisyn

Improvac

Trifexis

Galliprant

Intercept

8. Elanco Animal Health Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Elanco Animal Health Incorporated passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

12.e Scoring ^Insights

12.f DCF ^BETA